Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.344
Neutral
RSI(14)
43.208
Neutral
STOCH(KDJ)(9,3,3)
32.618
Sell
ATR(14)
0.854
Low Volatility
CCI(14)
-189.312
Sell
Williams %R
84.173
Oversold
TRIX(12,20)
0.111
Sell
StochRSI(14)
0.000
Sell
Search
Korro Bio Inc
KRROAdd to Watchlist
12.050USD
-0.840-6.52%
Close 05/08, 16:00（ET）Quotes delayed by 15 min
173.79MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Korro Bio Inc
Currency: USD Updated: 2026-05-08Key Insights
Korro Bio Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered undervalued, ranking 144 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.75.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Korro Bio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Korro Bio Inc Highlights
StrengthsRisks
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.39M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 6.39M.
Overvalued
The company’s latest PE is -1.03, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 11.34M shares, increasing 2.41% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 74.90K shares of this stock.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
19.750
Target Price
+53.22%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-08The current financial score of Korro Bio Inc is 5.69, ranking 327 out of 384 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 16.09%.
Score
Financials
5.55
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.61
Operational Efficiency
2.84
Growth Potential
5.35
Shareholder Returns
7.08
Korro Bio Inc's Company Valuation
Currency: USD Updated: 2026-05-08The current valuation score of Korro Bio Inc is 5.86, ranking 348 out of 384 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.03, which is -45.65% below the recent high of -0.56 and -411.18% above the recent low of -5.27.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 144/384
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-08The current earnings forecast score of Korro Bio Inc is 8.00, ranking 161 out of 384 in the Biotechnology & Medical Research industry. The average price target is 9.50, with a high of 147.00 and a low of 7.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
19.750
Target Price
+53.22%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
553
Total
6
Median
6
Average
Company name
Ratings
Analysts
Korro Bio Inc
KRRO
10
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
27
argenx SE
ARGX
26
Beigene Ltd
ONC
25
Ionis Pharmaceuticals Inc
IONS
23
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-08The current price momentum score of Korro Bio Inc is 6.39, ranking 267 out of 384 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 13.86 and the support level at 10.93, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
12.780
Sell
MA10
12.921
Sell
MA20
13.331
Sell
MA50
12.430
Sell
MA100
11.286
Buy
MA200
18.655
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-08The current institutional shareholding score of Korro Bio Inc is 7.00, ranking 79 out of 384 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 82.84%, representing a quarter-over-quarter decrease of 29.42%. The largest institutional shareholder is Steven Cohen, holding a total of 816.88K shares, representing 5.66% of shares outstanding, with 2.11% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Lynx1 Capital Advisors LLC
New Enterprise Associates (NEA)
Atlas Venture
VR Adviser, LLC
Nantahala Capital Management, LLC
Vanguard Investments Australia Ltd.
BlackRock Institutional Trust Company, N.A.
TCG Crossover Management, LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-05-08The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Korro Bio Inc is 1.27, ranking 318 out of 384 in the Biotechnology & Medical Research industry. The company's beta value is 3.05. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
3.06
VaR
+9.09%
240-Day Maximum Drawdown
+89.72%
240-Day Volatility
+188.09%
Return
Best Daily Return
60 days
+11.75%
120 days
+14.39%
5 years
+5066.89%
Worst Daily Return
60 days
-7.31%
120 days
-79.31%
5 years
-80.54%
Sharpe Ratio
60 days
+0.33
120 days
-0.04
5 years
+0.47
Risk Assessment
Maximum Drawdown
240 days
+89.72%
3 years
+94.13%
5 years
+98.76%
Return-to-Drawdown Ratio
240 days
-0.14
3 years
-0.11
5 years
-0.20
Skewness
240 days
-3.97
3 years
+26.76
5 years
+34.50
Volatility
Realised Volatility
240 days
+188.09%
5 years
+157.70%
Standardised True Range
240 days
+16.04%
5 years
+56.48%
Downside Risk-Adjusted Return
120 days
-3.59%
240 days
-3.59%
Maximum Daily Upside Volatility
60 days
+88.11%
Maximum Daily Downside Volatility
60 days
+55.57%
Liquidity
Average Turnover Rate
60 days
+1.96%
120 days
+3.64%
5 years
--
Turnover Deviation
20 days
-53.36%
60 days
-4.84%
120 days
+76.96%
Peer Comparison
Biotechnology & Medical Research
Korro Bio Inc
KRRO
6.01 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AnaptysBio Inc
ANAB
8.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
